Cargando…
Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease: Erratum
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400358/ https://www.ncbi.nlm.nih.gov/pubmed/31265635 http://dx.doi.org/10.1097/01.md.0000494747.37187.c1 |
Ejemplares similares
-
Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease
por: Su, Vincent Yi-Fong, et al.
Publicado: (2016) -
Carvedilol in the treatment of chronic heart failure: Lessons from The Carvedilol Or Metoprolol European Trial
por: Kveiborg, Britt, et al.
Publicado: (2007) -
Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10‐Year Cohort
por: Tang, Chao‐Hsiun, et al.
Publicado: (2016) -
Differential Effects of the Betablockers Carvedilol, Metoprolol and Bisoprolol on Cardiac K(v)4.3 (I(to)) Channel Isoforms
por: Rahm, Ann-Kathrin, et al.
Publicado: (2023) -
The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction
por: Choi, Ki Hong, et al.
Publicado: (2019)